H1 2026 GLP-1 Provider Report Card: Who Earned an A and Who Needs Improvement

January 2026 and July 2026 feel like different eras in the GLP-1 telehealth market. In January, oral Wegovy didn't exist. Medicare didn't cover GLP-1s for weight loss. Brand-name injectables still cost $500+/month without insurance. The compounded market was the only affordable option for most cash-pay patients.

Six months later, every one of those facts has changed. And how providers responded to these changes — proactively, reactively, or not at all — tells you everything about which ones deserve your business heading into H2 2026.

The Five Forces That Reshaped H1 2026

Before the grades, the context. Five market developments forced every provider to adapt:

1. Oral Wegovy launch ($149/month). An FDA-approved, brand-name GLP-1 in pill form at a price point competitive with many compounded injectables. This changed the calculus for needle-averse patients and compressed the pricing advantage compounded providers had enjoyed.

2. Brand-name price cuts. Novo Nordisk and Eli Lilly both cut self-pay prices in late 2025 and early 2026. Injectable Wegovy at $349/month and Zepbound starting at $299/month brought brand-name options within reach for patients who previously couldn't consider them.

3. Medicare GLP-1 Bridge. The most significant insurance expansion in the GLP-1 market's history — Medicare Part D coverage for weight-loss GLP-1s at approximately $50/month, launching July 1, 2026. This created a massive new patient population with brand-name access.

4. Regulatory uncertainty. Ongoing questions about the FDA shortage list, 503B compounding regulations, and state-level telehealth prescribing rules kept providers and patients on edge throughout H1.

5. Market saturation. New GLP-1 telehealth providers continued to enter the market, increasing competition and putting downward pressure on margins. Providers that didn't differentiate on clinical quality or patient experience found themselves competing purely on price — a race to the bottom.

The Report Card

Grade: A — Adapted, Improved, Leading

Embody

Embody maintained its clinical-first positioning throughout a period of market turbulence. The $149 first-month pricing remained competitive even as brand-name options got cheaper, and the dedicated provider model continued to differentiate from form-and-ship competitors. Their focus on injectable semaglutide quality — rather than chasing every new format — showed strategic discipline. Heading into H2, Embody is well-positioned as the clinical-quality leader in the compounded space.

GobyMeds

GobyMeds proved that budget pricing and reliability can coexist. Throughout H1 2026, they maintained $99/month semaglutide and $133/month tirzepatide without supply disruptions, shipping delays, or quality issues. In a market where some budget providers appeared and disappeared within months, GobyMeds' consistency at the lowest price point earned them an A. The model is lean, but it works.

Grade: A- — Strong Performance, Minor Gaps

Sesame Care

Sesame Care's brand-name consultation model became more relevant with every price cut from Novo Nordisk and Eli Lilly. As brand-name GLP-1s got cheaper, Sesame's affordable consultations ($49/visit) became an increasingly compelling pathway to FDA-approved medications. The main gap: their platform doesn't aggregate brand-name pricing options for patients, so patients still need to research NovoCare, LillyDirect, and insurance options independently after the consultation.

Found Health

Found's holistic model — coaching, nutrition, behavioral support, and GLP-1 prescribing — continued to differentiate in H1. The integrated approach becomes more valuable as the market commoditizes pure prescription access. Minor gap: Found's pricing structure makes it harder for patients to compare their all-in cost against prescription-only competitors.

Grade: B+ — Solid but Room to Improve

Ivim Health

Ivim's insurance concierge model became more valuable as brand-name pricing improved and Medicare coverage launched. Their dual-pathway approach (brand-name via insurance, compounded as fallback) is well-suited for the current market. The B+ rather than A reflects that their compounded pricing could be more competitive for patients who don't have insurance coverage.

Yucca Health

Yucca's bundle pricing and provider onboarding calls remained differentiators throughout H1. The 6-month commitment model works for dedicated patients but is less attractive in a market where patients increasingly want month-to-month flexibility to switch between compounded and brand-name options as pricing shifts.

Care Bare Rx

Care Bare's same-price-at-every-dose model is a genuine consumer-friendly innovation that deserves more recognition. Solid H1 performance with predictable pricing and straightforward service. The B+ reflects that they could do more to differentiate on clinical support — predictable pricing solves one problem, but patients increasingly want more from their provider relationship.

Grade: B — Adequate, But Watch Closely

These providers maintained adequate service throughout H1 2026 without significant issues — but also without significant differentiation. In a market with 20+ viable options, "adequate" is no longer a competitive advantage. Heading into H2, providers in this tier need to articulate a clearer value proposition: why choose them over the A-grade leaders above?

Grade: C — Concerns Flagged

MEDVi

MEDVi's February 2026 FDA warning letter is the defining event of their H1. While they've stated they're addressing the FDA's concerns, the warning letter remains on the public record and represents a significant trust issue. Patients considering MEDVi should review the FDA's letter directly. We've removed MEDVi from featured recommendations pending resolution.

What H2 2026 Will Bring

Looking ahead, several developments will pressure providers to continue adapting:

• Medicare coverage matures. As Medicare patients begin accessing $50/month brand-name GLP-1s en masse, compounded providers serving the 65+ demographic will face significant competition.
• Orforglipron FDA decision. Eli Lilly's oral GLP-1 pill could receive FDA approval in late 2026, adding another brand-name oral option and further compressing the compounding market's pricing advantage.
• IRA-negotiated pricing approaching. January 2027 brings Medicare-negotiated semaglutide pricing, creating additional downward pressure on the entire market.
• Continued regulatory scrutiny. The FDA shortage list status for GLP-1 medications remains a wild card that could reshape compounding access at any time.

The providers earning A grades today are the ones most likely to navigate these changes successfully — because they've already demonstrated the adaptability and patient focus required to thrive in a market that refuses to stand still.